RFCA
IMGN

R&F Capital Advisors’s Immunogen Inc IMGN Stock Holding History

R&F Capital Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$68K Buy
+17,649
New +$51.5K 0.02% 637

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R&F Capital Advisors's IMGN Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Immunogen Inc (IMGN) in Q1 2017: 17,649 shares worth $68K. The stake represents 0.02% of the portfolio and ranks #637 among its holdings.

135 funds tracked by Wall St. Rank hold IMGN as of Q1 2017.

  • R&F Capital Advisors held 17,649 shares of Immunogen Inc worth $68K as of Q1 2017.
  • Immunogen Inc was a new R&F Capital Advisors position in Q1 2017.
  • Immunogen Inc made up 0.02% of R&F Capital Advisors's portfolio in Q1 2017, its #637 holding.
  • 135 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.